蜜桃传媒破解版

Read time: 4.5 minutes

Imagine if one of your family members was told she had blood cancer. The reality is that most traditional therapies used to treat this type of cancer don鈥檛 have a positive track record. Yet there are promising new therapies emerging, such as chimeric antigen receptor (CAR) T-cell therapies, which involve taking a type of white blood cell, called T cells, from a patient鈥檚 blood and genetically changing them to fight the cancer in the patient鈥檚 body. These types of therapies are already giving many patients battling blood cancers a fighting chance.

Currently, there are dozens of emerging biopharma companies that are working toward solving some of the biggest healthcare challenges we face today in many therapeutic areas, including in oncology. And while there is tremendous hope in their work, the logistical challenges that may come their way ahead of receiving approval by the U.S. Food and Drug Administration (FDA) can be daunting. How can they set up an operation to support the distribution of their new drugs? What investment is required for them to commercialize their medicines?

That鈥檚 exactly where 蜜桃传媒破解版 Third Party Logistics^SM (3PL) comes in to support biopharma companies of all sizes, with everything from overseeing licensing needs and business continuity planning to monitoring programming, and so much more.

鈥淲hether it鈥檚 playing an important role for therapies like CAR T, moving raw plasma from collection centers and then back to providers as finished and approved products, or managing incredibly high-volume generic drugs, we鈥檝e designed a comprehensive set of offerings that enable biopharma companies to focus on what they do best 鈥� helping patients with different treatment options,鈥� says James Canham, vice president of client services, 蜜桃传媒破解版 3PL. 鈥淚n fact, we take great pride in our ability to step in seamlessly and help simplify the commercialization process, which is especially important for customers who may not have the infrastructure or capabilities internally to get their therapies to patients in need.鈥�

Specialty Medications Create New Challenges

One of the most important emerging needs coming from biopharma companies is having flexible specialty therapy capabilities for a variety of new therapies. Whether it鈥檚 the ability to handle unique cold chain requirements (as is required by most COVID-19 vaccines), regulatory expertise needed to remain compliant (including updates required by the (DSCSA), or the technology capabilities needed to deliver data-driven insights, the role of 3PL is rapidly advancing as new specialty medications hit the marketplace at record rates.

Yet the continued onset of new and innovative types of therapies has challenged the way distribution has been managed to date which requires ingenuity to develop new delivery management systems in real time.

鈥淎s one of the country鈥檚 biggest 3PL players in healthcare, we continue to leverage our decades of distribution expertise to support the complex needs of our biopharma partners,鈥� Canham explains. 鈥淚n addition to our experience, our business is also fueled by innovation that helps us continue to meet the needs of novel therapies. By looking at what鈥檚 happening in drug R&D and pairing those insights with what we hear our customers say they need, we鈥檙e able to evolve with 鈥� and sometimes even stay a step ahead 鈥� of our industry. That鈥檚 something we know is important to the customers we serve. The therapies are complex, the market is complex, and things like regulatory changes 鈥� or even a pandemic 鈥� require us to move fast.鈥�

It鈥檚 also essential to provide the right level of service based on the class of medications. For example, some therapies might require a secure and compliant controlled substance monitoring program inclusive of dedicated quality oversight and reporting, while others might need same-day and after-hour shipments for products with highly sensitive temperature requirements.

鈥淲e take great pride in our ability to step in seamlessly and help simplify the commercialization process.鈥�

Licensing Needs

Another challenge many of the smaller biopharma companies face is the ability to secure licensing across all states, which basically means a medication must be approved to distribute it within the state, even if it has been cleared by the FDA.

鈥淚n recent years, we've seen a real demand to support title and non-title licensing needs,鈥� says Bill Little, vice president of integrated logistics solutions, 蜜桃传媒破解版 3PL. 鈥淥ur model is ideal for biopharma programs who have not completed the process of acquiring state licenses before a product launch, which can be both time- and resource-intensive.鈥�

蜜桃传媒破解版 solves for this by offering a title model, leveraging its own distribution licenses to purchase the products from the biopharma company and then selling the products to customers based on contractual requirements. This model allows companies that do not have the resources to gain all the state licenses to go to market much sooner. In 蜜桃传媒破解版鈥檚 non-title model, 蜜桃传媒破解版 acts as the biopharma company鈥檚 agent to ship and sell product on their behalf. Offering both models allows 蜜桃传媒破解版 to cater to the company鈥檚 needs, no matter what they may be.

鈥淲e are energized by all the advancements in therapy development and believe that we have the right people in place to help any biopharma company 鈥� big or small 鈥� with any of their unique needs,鈥� Canham concludes.

Now think back to your family member with a rare blood cancer. This expensive, logistically complex CAR T therapy is finally administered to your family member, and you can begin to feel a sense of hope.

And while other new medications are on the rise and the progress in personalized medicine is changing lives, 蜜桃传媒破解版鈥檚 3PL is positioned to play distinct role in the ultimate pursuit: improving patient outcomes.